Document is current
Any future updates will be listed below
-
Authors
Lim, Yoong Wearn https://orcid.org/0000-0002-8568-4901
Ramirez, Neftali Jose https://orcid.org/0000-0002-7942-6762
Asensio, Michael A. https://orcid.org/0000-0001-9087-0568
Chiang, Yao
Müller, Gabriele
Mrovecova, Pavla
Mitsuiki, Noriko https://orcid.org/0000-0002-0128-6907
Krausz, Máté https://orcid.org/0000-0002-0385-033X
Camacho-Ordonez, Nadezhda https://orcid.org/0000-0001-6722-7427
Warnatz, Klaus https://orcid.org/0000-0002-1172-865X
Adler, Adam S. https://orcid.org/0000-0001-9301-0037
Grimbacher, Bodo https://orcid.org/0000-0002-6897-6806
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GR1617/14-1/iPAD, RESIST–EXC 2155–Project ID 390874280, CIBSS–EXC-2189–Project ID 390939984, SFB1160_2)
Deutsche Forschungsgemeinschaft (SFB1160/2_B5)
Bundesministerium für Bildung und Forschung (GAIN 01GM1910A)
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 7 February 2023
First Online: 24 February 2023
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Freiburg, Germany. Ethics number: EK-FR_295/13_200149; 2020/03/12.
: Patients were included into the study following an informed consent procedure approved by the Ethics committee of the University.
: Patients signed informed consent regarding publishing their pseudoanonymized data and researchers only worked with coded samples.
: YWL, MAA, YC, and ASA are employees of GigaGen, Inc. (A Grifols Company), and receive salary for their work. BG is employed by the University Hospital Freiburg, Germany, and currently receives funding for his research from following third parties: Deutsche Forschungsgemeinschaft (DFG); the E-rare program of the EU, managed by the DFG; the “Netzwerke Seltener Erkrankungen” of the German Ministry of Education and Research (BMBF). During the last 3 years, BG was an advisor to the following companies receiving fees less than 1000€: Bristol-Myers Squibb Company, Adivo Associates Germany, Pharming Group NV, Epimune GmbH, GigaGen Inc., Atheneum Partners GmbH; and less than 5000€: UCB Pharma S.A., Roche Pharma AG.
